Trastuzumab, Nivolumab and Keytruda: Our Bureau, Bengaluru Wednesday, January 7, 2026, 11:30 Hrs [IST] Biocon Biologics, ...
CT scan of chest, abdomen, and pelvis shows high-disease burden, including multiple mediastinal and hilar nodes, deposits in ...
Also highlight plans to integrated with Biocon at 44th Annual J.P. Morgan Healthcare Conference in San Francisco ...
Biocon Biologics is set to unveil three new biosimilar oncology assets — Trastuzumab/Hyaluronidase (Herceptin SC/Herceptin HYLECTA), Nivolumab (Opdivo), and Pembrolizumab (Keytruda) — at the 2026 JP ...
Biocon Biologics to launch Trastuzumab, Nivolumab, Pembrolizumab biosimilars for cancer. Expanding oncology portfolio.
Biocon Biologics plans to introduce three oncology biosimilars, enhancing its cancer treatment portfolio. They will unveil ...
He will also participate in a fireside chat at the ENDPOINTS at JPM26 conference on Tuesday, January 13 titled, "Achieving ...
Immune checkpoint inhibitors have significantly improved survival for a variety of malignancies over the past decade, but the costs of these medications have barely changed.An investigation into 11 ...
Beyond hazard ratios, investigators used restricted mean survival time (RMST) analysis to compare survival gains across trialed ICI combinations for mRCC.
Objective To estimate the budget impact of using nivolumab and pembrolizumab in the treatment of metastatic melanoma in Brazil. Methods This was a retrospective budget impact analysis using data from ...
The updated guidelines reflect major shifts driven by Phase III data supporting immunotherapy use around the time of surgery. Surgical resection remains the foundation for early-stage disease; however ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback